Healthcare
TELA Bio, Inc.(TELA)
Live Price
Offline$0.801
-6.75% today
1Y Change
-53.70%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $40.00M
- Revenue Growth
- +15.8%
- EPS Growth
- +37.6%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TELA Bio, Inc. (TELA) is a Healthcare stock with a market cap of $40.00M and listed on NASDAQ. The stock last traded around $0.80 and down 53.7% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +15.8%, EPS growth of +37.6%, a dividend yield of 0.0%. What stands out right now is revenue +15.8%, EPS +37.6%, free cash flow +32.7% with operating margin -42.0% and ROIC -53.2%. Valuation is more restrained than many high-expectation growth names at price/sales 0.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TELA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+15.8% vs +7.6% peer median
Operating Margin
Below sector median
-42.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +15.8% and EPS at +37.6%, with operating margin around -42.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -9.9% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -8.6% | -6.8% | -13.1% |
2026 Mar 24, 2026 | +11.1% | -9.3% | -18.5% | -17.9% |
2025 Nov 13, 2025 | -11.8% | -10.0% | -4.5% | +3.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TELA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TELA Max Drawdown
-73.83%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TELA and SPY.
Company Overview
TELA Bio, Inc.
NASDAQ Global Market
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
- Leadership
- Antony Koblish
- IPO Date
- Nov 8, 2019
- Employees
- 209
- Street Address
- 1 Great Valley Parkway
- Mailing
- Malvern, PA, 19355
- Region
- Malvern, PA, US
- Reporting Currency
- USD
- Investor Line
- 484 320 2930
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.6
- Price/Book
- 8.1
Growth
- Revenue
- +15.8%
- EPS
- +37.6%
- Free Cash Flow
- +32.7%
Profitability
- Gross Margin
- 67.7%
- Operating Margin
- -42.0%
- Net Margin
- -48.4%
- ROE
- -441.5%
- ROIC
- -53.2%
Balance Sheet
- Debt/Equity
- 8.82
- Current Ratio
- 4.20
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.